Most cited papers from Theracos (United States)

Theracos (United States)

What are the most cited papers from Theracos (United States)?

The most cited paper from Theracos (United States) is "EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats" (Wenbin Zhang, Ajith A. Welihinda, Jordan Mechanic et al., 2011), with 76 citations. Next come "Design, Synthesis, and Biological Evaluation of Deuterated C-Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes" (66) and "A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes" (43).

Published FieldAccess

Showing 10 of 10 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats Wenbin Zhang, Ajith A. Welihinda, Jordan Mechanic et al. · Pharmacological Research	6 Jan 2011	76
2	Design, Synthesis, and Biological Evaluation of Deuterated C-Aryl Glycoside as a Potent and Long-Acting Renal Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Ge Zhi Xu, Binhua Lv, Jacques Y. Roberge et al. · Journal of Medicinal Chemistry Open access	23 Jan 2014	66
3	A 96‐week, multinational, randomized, double‐blind, parallel‐group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes Yuan‐Di C. Halvorsen, Geoffrey A Walford, Joseph M. Massaro et al. · Diabetes Obesity and Metabolism	12 Jul 2019	43
4	Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors Binhua Lv, Baihua Xu, Feng Yun Yan et al. · Bioorganic & Medicinal Chemistry Letters Open access	24 Oct 2009	37
5	C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes Baihua Xu et al. · Bioorganic & Medicinal Chemistry Letters Open access	25 Jun 2011	33
6	A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults Yuan‐Di C. Halvorsen, John Paul Lock, Juan P. Frías et al. · Diabetes Obesity and Metabolism Open access	30 Sep 2022	26
7	O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors Baihua Xu, Binhua Lv, Feng Yun Yan et al. · Bioorganic & Medicinal Chemistry Letters Open access	13 Aug 2009	26
8	ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors Baihua Xu, Feng Yun Yan, Binhua Lv et al. · Bioorganic & Medicinal Chemistry Open access	May 2010	23
9	Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) Inhibitors Binhua Lv, Feng Yun Yan, Jiajia Dong et al. · ChemMedChem	22 Apr 2010	20
10	Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial Lingding Xie, Jie Han, Zhifeng Cheng et al. · Journal of Diabetes Open access	Apr 2024	8

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.